Vaxart, Inc. (NASDAQ:VXRT) SVP Margaret Echerd sold 1,801 shares of the firm’s stock in a transaction dated Friday, September 10th. The stock was sold at an average price of $9.10, for a total transaction of $16,389.10. Following the sale, the senior vice president now directly owns 334 shares in the company, valued at $3,039.40. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Margaret Echerd also recently made the following trade(s):
- On Monday, July 19th, Margaret Echerd sold 1,800 shares of Vaxart stock. The stock was sold at an average price of $8.00, for a total transaction of $14,400.00.
NASDAQ VXRT opened at $8.12 on Wednesday. Vaxart, Inc. has a one year low of $3.50 and a one year high of $24.90. The company’s 50 day moving average price is $8.30 and its 200 day moving average price is $7.37. The firm has a market capitalization of $997.28 million, a price-to-earnings ratio of -16.92 and a beta of 0.31.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sowell Financial Services LLC raised its stake in shares of Vaxart by 1,194.8% during the first quarter. Sowell Financial Services LLC now owns 5,179 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 4,779 shares during the period. BNP Paribas Arbitrage SA grew its position in shares of Vaxart by 32.4% during the first quarter. BNP Paribas Arbitrage SA now owns 7,383 shares of the biotechnology company’s stock worth $45,000 after buying an additional 1,805 shares in the last quarter. Teacher Retirement System of Texas acquired a new stake in shares of Vaxart during the first quarter worth approximately $68,000. Ameritas Investment Partners Inc. grew its position in shares of Vaxart by 111.5% during the second quarter. Ameritas Investment Partners Inc. now owns 9,366 shares of the biotechnology company’s stock worth $70,000 after buying an additional 4,937 shares in the last quarter. Finally, US Bancorp DE acquired a new stake in shares of Vaxart during the second quarter worth approximately $75,000. Hedge funds and other institutional investors own 28.32% of the company’s stock.
Several research analysts have recently weighed in on VXRT shares. Piper Sandler started coverage on shares of Vaxart in a report on Friday, June 11th. They set an “overweight” rating and a $18.00 price objective on the stock. Zacks Investment Research lowered shares of Vaxart from a “buy” rating to a “hold” rating in a report on Thursday, September 2nd. Jefferies Financial Group started coverage on shares of Vaxart in a report on Thursday, June 24th. They set a “buy” rating and a $13.00 price objective on the stock. Finally, B. Riley lowered shares of Vaxart from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $13.00 to $9.00 in a report on Tuesday, June 29th.
Vaxart, Inc operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
Featured Story: ESG Score
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.